Table 2.
Comparison between antibody-acquired and non-acquired groups.
| Antibody positive (n = 23) |
Antibody negative (n = 50) |
P value | |
|---|---|---|---|
| Age at the time of vaccination, year, median [IQR] | 59 [49, 69] | 64 [50, 69] | 0.392 |
| Age at the time of transplantation, year, median [IQR] | 50 [37, 55] | 56 [45, 62] | < 0.05 |
| Male, n (%) | 16 (69.6) | 29 (58.0) | 0.493 |
| Height, cm, median [IQR] | 165.8 [160.1, 169.6] | 162.0 [154.8, 168.9] | 0.269 |
| Weight, kg, median [IQR] | 64.2 [57.2, 78.2] | 57.7 [51.9, 68.6] | < 0.05 |
| BMI, kg/m2, median [IQR] | 23.7 [22.2, 27.2] | 22.2 [20.6, 24.6] | < 0.05 |
| eGFR, mL/min/1.73m2, median [IQR] | 47.4 [39.4, 54.4] | 41.1 [30.4, 49.3] | < 0.05 |
| The duration between transplantation and vaccination, month, median [IQR] | 81 [48, 160] | 66 [23, 119] | < 0.05 |
| The duration from vaccination to antibody assay, day, median [IQR] | 44 [32, 58] | 40 [30, 52] | 0.419 |
| Primary kidney diseases, n (%) | 0.494 | ||
| Chronic glomerulonephritis | 11 (47.8) | 15 (30.0) | |
| Diabetic nephropathy | 2 (8.7) | 8 (16.0) | |
| Hereditary disease | 1 (4.3) | 8 (16.0) | |
| Nephrosclerosis | 1 (4.3) | 2 (4.0) | |
| Focal segmental glomerulosclerosis | 1 (4.3) | 2 (4.0) | |
| Coexisting disease, n (%) | |||
| Diabetes mellitus | 7 (30.4) | 15 (24.0) | 0.768 |
| Hypertension | 13 (56.5) | 37 (74.0) | 0.222 |
| Types of transplants, n (%) | |||
| Deceased donor kidney transplants | 2 (8.7) | 4 (8.0) | 1.000 |
| Living-donor kidney transplants | 21 (91.3) | 46 (92.0) | 1.000 |
| ABO-incompatible kidney transplants | 6 (26.1) | 18 (36.0) | 0.569 |
| Preemptive kidney transplant, n (%) | 7 (30.4) | 23 (46.0) | 0.317 |
| White blood cell counts immediately prior to vaccination, 103/μl, [IQR] | 7.2 [5.9, 8.3] | 6.5 [5.3, 7.5] | 0.121 |
| Lymphocyte counts immediately prior to vaccination, 103/μl, [IQR] | 1.9 [1.6, 2.2] | 1.4 [1.1, 2.1] | < 0.05 |
| Types of immunosuppressive drugs, n (%) | |||
| Mycophenolate mofetil | 22 (95.7) | 49 (98.0) | 1.000 |
| Tacrolimus | 18 (78.3) | 47 (94.0) | 0.110 |
| Cyclosporine | 4 (17.4) | 3 (6.0) | 0.268 |
| Dose of immunosuppressive drugs, mg/day, median [IQR] | |||
| Prednisolone | 5.0 [5.0, 5.0] | 5.0 [5.0, 5.0] | 0.148 |
| Mycophenolate mofetil | 1000 [750, 1250] | 1000 [750, 1000] | 0.607 |
| Tacrolimus | 2.8 [2.0, 3.8] | 3.5 [2.0, 4.0] | 0.266 |
| Cyclosporine | 90 [75, 100] | 110 [105, 130] | 0.099 |
| Types of SARS-CoV-2 vaccine, n (%) | < 0.05 | ||
| Pfizer-BioNTech | 14 | 38 | |
| Moderna | 8 | 5 | |
| Unknown | 1 | 7 | |
IQR, interquartile range; BMI, body mass index; eGFR, estimated glomerular filtration rate.